Atezolizumab/ipilimumab/nivolumabLymphocytic colitis : 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1700卷 / 1期

关键词：

D O I：

10.1007/s40278-018-45619-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：47 / 47

相关论文

共 50 条

[21] Atezolizumab/Ipilimumab/NivolumabType 1 diabetes mellitus and isolated adrenocorticotropic hormone deficiency: 3 case reports
Reactions Weekly, 2024, 2021 (1) : 91 - 91
[22] Atezolizumab/ipilimumabMyocarditis: 3 case reports
Reactions Weekly, 2023, 1986 (1) : 76 - 76
[23] Ipilimumab/nivolumab/pembrolizumabEncephalopathy, colitis and acquired resistance to pembrolizumab and ipilimumab: 4 case reports
Reactions Weekly, 2019, 1768 (1) : 199 - 199
[24] Durvalumab/ipilimumab/tremelimumabChronic active colitis and enteritis treated with mesalamine: 3 case reports
Reactions Weekly, 2018, 1699 (1) : 109 - 109
[25] Durvalumab/ipilimumab/tremelimumabChronic active colitis and enteritis treated with mesalamine: 3 case reports
Reactions Weekly, 2018, 1700 (1) : 109 - 109
[26] Ipilimumab/nivolumab/pembrolizumabImmune-related colitis, pneumonitis and thyroiditis: 3 case reports
Reactions Weekly, 2023, 1948 (1) : 246 - 246
[27] Ipilimumab/nivolumab/pembrolizumabImmune-related colitis, sinusitis and conjunctivitis: 3 case reports
Reactions Weekly, 2024, 2036 (1) : 235 - 235
[28] Ipilimumab/nivolumabImmunotherapy-induced colitis: 4 case reports
Reactions Weekly, 2023, 1965 (1) : 259 - 259
[29] Infliximab/ipilimumab/nivolumabLack of efficacy and colitis: 2 case reports
Reactions Weekly, 2022, 1931 (1) : 314 - 314
[30] Ipilimumab/nivolumabLack of efficacy and autoimmune colitis: 2 case reports
Reactions Weekly, 2024, 2035 (1) : 252 - 252

← 1 2 3 4 5 →